News from qiagen A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

Dec 15, 2017, 15:05 ET QIAGEN and Oxford Immunotec Settle Patent Infringement Lawsuit

QIAGEN N.V. (NASDAQ: QGEN, Frankfurt Stock Exchange: QIA) and Oxford Immunotec Ltd. (NASDAQ: OXFD) announced today that they have reached a...


Nov 15, 2017, 15:05 ET QIAGEN Advances Precision Medicine by Automating Guidelines on Cancer Variants in Industry-leading QIAGEN Clinical Insight Software

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today launched enhancements in its QIAGEN Clinical Insight (QCI) bioinformatics software...


Oct 19, 2017, 16:36 ET QIAGEN Announces High Accuracy of Bioinformatics Solutions in Women's Health Genetic Screening

QIAGEN (NASDAQ: QGEN; Frankfurt Stock Exchange: QIA) today announced the results of a study evaluating the accuracy of the QIAGEN Clinical Insight...


Oct 05, 2017, 16:05 ET QIAGEN Launches Fourth-generation QuantiFERON®-TB Gold Plus in the U.S.

QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of QuantiFERON®-TB Gold Plus (QFT®-Plus), the fourth generation...


Jul 13, 2017, 04:02 ET QIAGEN N.V. to Report Second Quarter and First Half of 2017 Results

QIAGEN N.V. (Nasdaq: QGEN) (Frankfurt: QIA) plans as previously announced to release its report on results for the second quarter and first half of...


Jun 22, 2017, 08:04 ET French health system approves reimbursement of QIAGEN's QuantiFERON latent TB test

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that France's Ministry of Health and Social Affairs has approved...


Jun 08, 2017, 09:00 ET QIAGEN's QuantiFERON®-TB Gold Plus gains U.S. FDA approval

QIAGEN N.V. (NASDAQ: QGEN) (Frankfurt Prime Standard: QIA) today announced the U.S. regulatory approval of QuantiFERON®-TB Gold Plus (QFT®-Plus) the...


Jun 06, 2017, 02:00 ET QIAGEN receives U.S. FDA approval for cytomegalovirus (CMV) testing on automated QIAsymphony platform

QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received premarket approval from the U.S. Food and Drug Administration...


Jun 03, 2017, 13:00 ET QIAGEN expands biomarker content portfolio to support greater use of molecular diagnostics for immuno-oncology therapies

QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received a worldwide license from The Johns Hopkins University for...


Jun 03, 2017, 13:00 ET Bristol-Myers Squibb and QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies

Bristol-Myers Squibb Company (NYSE: BMY) and QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) have signed an agreement to explore the use of...


Nov 09, 2016, 02:05 ET QIAGEN's GeneReader NGS System Streamlines Data Management for Labs

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with lab informatics company Genohm to empower GeneReader NGS ...


Aug 14, 2016, 08:59 ET QIAGEN gibt Pläne zur Rückzahlung von rund 250 Mio. USD an Aktionäre mittels synthetischen Aktienrückkaufs bekannt

Das Angebot würde durch die Reduzierung des Volumens der ausstehenden Aktien um ungefähr 4 % und eine unmittelbare Kapitalauszahlung an die Aktionäre ...


Aug 14, 2016, 08:48 ET QIAGEN Announces Plans to Return Approximately $250 Million to Shareholders Via Synthetic Share Repurchase Proposal

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced plans to return approximately $250 million to shareholders through a...


Jul 14, 2016, 05:14 ET QIAGEN N.V. to Report Second Quarter and First Half of 2016 Results

QIAGEN N.V. (Nasdaq: QGEN) (Frankfurt: QIA) plans as previously announced to release its report on results for the second quarter and first half of...


Apr 14, 2016, 04:05 ET QIAGEN bringt optimierte Bioinformatik-Lösungen für die Analyse von RNA-Sequenzdaten aus Flüssigbiopsien auf den Markt

Die RNA-seq-Explorer-Lösung liefert eindeutige Erkenntnisse für "Omics"-Analysen in der Krebsforschung QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime...


Apr 14, 2016, 04:05 ET QIAGEN Launches Streamlined Bioinformatics for RNA Sequencing of Liquid Biopsies

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced introduction of its unique RNA-seq Explorer Solution, a...


Feb 15, 2016, 04:05 ET Multizentrische Studie bestätigt Nutzen des QuantiFERON®-TB Gold Plus Tests von QIAGEN

Europaweite Studie belegt verbesserte Sensitivität des Tests der vierten Generation zum Nachweis von Tuberkuloseinfektionen QIAGEN N.V. (NASDAQ:...


Jan 26, 2016, 02:00 ET QIAGEN liefert QuantiFERON-TB-Tests, um Tuberkulin-Engpass zu begegnen

In Zeiten des Flüchtlingszustroms setzen deutsche Gesundheitsbehörden auf moderne Bluttests für Kinder Das Deutsche Zentralkomitee zur Bekämpfung der ...


Jan 26, 2016, 02:00 ET QIAGEN to Supply QuantiFERON-TB Tests to Ease Tuberculin Shortage

The German Central Committee against Tuberculosis (DZK) recommended that public health services and clinics should use modern blood tests to screen...


Nov 04, 2015, 04:05 ET QIAGEN führt GeneReader NGS System ein

Mit der ersten echten Komplettlösung rückt Next-Generation-Sequencing für jedes Labor in greifbare Nähe QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime...


Nov 04, 2015, 04:05 ET Evaluation Confirms: QIAGEN's New GeneReader NGS System Delivers Valuable Clinical Insights

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that an evaluation has affirmed the performance of the Company's GeneReader ...


Nov 04, 2015, 04:05 ET QIAGEN introduces GeneReader NGS System

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the start of commercialization activities for its GeneReader NGS System,...


Nov 04, 2015, 04:05 ET Evaluierung bestätigt: QIAGENs neues GeneReader NGS System liefert wertvolle klinische Erkenntnisse

Weltweit erste NGS-Komplettlösung von der Probe zur Erkenntnis erweist sich als gleichwertig oder besser als andere Sequenzierungslösungen und...


Nov 02, 2015, 04:05 ET QIAGEN erweitert Softwarelösung zur Unterstützung klinischer Entscheidungen auf Basis von NGS-Daten in der Onkologie

Neue Lösungen in QIAGEN Clinical Insight® für somatische und erbliche Krebserkrankungen QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) gab ...


Nov 02, 2015, 04:05 ET QIAGEN Expands Clinical Decision Support for NGS in Oncology Labs

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced enhancements to its QIAGEN Clinical Insight® (QCI™) clinical decision...